PXPXS RESEARCH
Earnings recap · Healthspan Infrastructure · 2026-07-01 to 2026-09-30

Healthspan — Earnings Call Recap (Q3 2026)

By Published by PXS Research Updated

Healthspan Infrastructure earnings-call recap for 2026-07-01 to 2026-09-30 · 1476 words · 10 sources

Overview

# Healthspan — Earnings Call Recap (Q3 2026)

Companies reporting: 10

Avg conviction adjustment: +0.04

Trend synthesis

The earnings season for the period ending September 30, 2026, revealed a Healthspan sector characterized by strong operational execution among diversified large-caps, contrasted with significant market-specific pressures and strategic investment cycles impacting smaller, more focused players. Dominant cross-company themes included broad-based procedural and instrument demand, a notable rebound in China, and the growing, tangible impact of AI in both drug discovery and medical technology ecosystems. While most large-cap MedTech and Life Sciences Tools companies raised full-year guidance on durable demand, others faced headwinds from competitive incursions and market shifts, leading to a bifurcation in performance and outlook.

Guidance and Outlook: A Story of Divergence

The guidance narrative for the quarter was largely positive for established, diversified players, who translated strong results into increased full-year confidence. MDT raised its FY2027 organic revenue growth guidance by 50 basis points to 7.25%-7.75% and lifted its adjusted EPS range to $5.94-$6.00, signaling broad-based strength. Similarly, A raised its FY2026 revenue guidance to $7.49-$7.51 billion and its non-GAAP EPS outlook to $6.18-$6.21, citing a strong quarter and an improved forecast for China. ABT also raised its full-year adjusted EPS guidance to a range of $5.45-$5.60 after a solid quarter. Based on its early August earnings call, TXG increased its full-year 2026 revenue outlook to $610-$630 million, driven by strong early demand for its new Atera platform.

However, this optimism was not universal. BSX provided a more cautious outlook, revising its FY2026 organic revenue growth guidance downward to 5-6% due to what it termed a "sharp and unexpected slowdown in the U.S. WATCHMAN market and competitive pressure in Electrophysiology." In a different vein, TMDX presented a mixed update, raising its full-year 2026 revenue guidance to $737-$757 million but lowering its adjusted operating margin guidance to 12.5%-14%. Per TMDX, this reflects a strategic decision to accelerate investments in its promising kidney program, prioritizing long-term market capture over near-term profitability. As a clinical-stage biotech, LTRN did not provide revenue or EPS guidance, instead focusing on its cash position of approximately $7.4 million as of June 30, 2026, which is critical for funding its ongoing trials.

End-market demand was healthy and durable across most of the sector, though specific product cycles and geographic performance varied. MDT reported powerful 13.7% organic revenue growth in its first quarter, citing broad-based strength across its Cardiovascular (up 18.9% organic), spine, and Surgical portfolios, describing the underlying markets as "healthy with durable demand." A delivered core revenue growth of 7.3%, beating its guidance, with strength in its pharma/biopharma end-markets and a significant rebound in China, where revenue grew 9% on what the company called "competitive wins." ABT also saw robust demand, with reported sales up 13.0%, led by its diagnostics and medical devices segments.

The story was more nuanced for companies with concentrated exposures. TMDX posted record Q2 revenue of nearly $190 million, a 21% year-over-year increase, driven by strong utilization of its Organ Care System (OCS) in liver and heart transplants. Conversely, BSX experienced a sharp divergence in its portfolio; while interventional cardiology and endoscopy performed well, this was offset by a mid- to high-single-digit decline in the WATCHMAN market, where it holds a dominant ~91% share. For tools companies, new product cycles were a key driver. Based on its Q2 call, TXG noted "exceptional early demand" and high order volume for its new Atera spatial biology platform, which is expected to drive a significant revenue step-up in the fourth quarter, even as overall instrument revenue declined year-over-year ahead of the launch. For pre-revenue biotechs like LTRN, demand is a function of clinical progress; the company highlighted deepening progression-free survival (PFS) benefits in its HARMONIC trial for non-small cell lung cancer as a key value driver.

Margin Commentary: Execution and Investment Trade-Offs

Margin performance reflected a split between companies realizing operating leverage and those investing heavily for future growth. A demonstrated strong execution, posting a non-GAAP operating margin of 28.3%, which included a ~110 basis point benefit from tariff refunds; excluding this, its margin expansion was still robust, driven by strategic pricing and efficiencies from its Ignite Operating System, per the call. MDT also delivered margin improvement, with adjusted gross margin up 10 basis points to 65.2%, and is targeting 50 basis points of operating margin expansion for the full fiscal year, supported by cost-control programs and pricing discipline. ABT similarly pointed to gross margin expansion from favorable product mix and cost mitigation efforts as a key factor supporting its EPS guidance raise.

In contrast, TMDX saw its adjusted operating margin decline to 13.6% from 23.2% in the prior year, a direct result of increased R&D spending on its kidney and next-generation platforms and SG&A for international expansion. Its gross margin also dipped to ~60% due to a mix shift toward its fast-growing but lower-margin logistics and services business, according to its call. BSX flagged future gross margin pressure stemming from the slowdown in its higher-margin WATCHMAN and Electrophysiology businesses. At the other end of the spectrum, LTRN showcased fiscal discipline, reporting that its Q2 loss from operations decreased approximately 25% year-over-year, largely due to a 42% reduction in R&D expenses.

AI and Digital Ecosystems: The Sector's Emerging Growth Driver

While not as pervasive as in the technology sector, AI and integrated data ecosystems are emerging as a critical theme and competitive differentiator. LTRN's entire corporate identity is built on this trend, describing itself as a "clinical-stage AI-driven precision oncology company" that leverages its proprietary RADR® AI platform to accelerate drug development. MDT explicitly highlighted its AiBLE ecosystem, which is designed to integrate AI-driven planning, navigation, and robotics to connect previously siloed technologies in its spine and cranial businesses. For TXG, AI is both a tool and a demand driver; its Q2 call noted growing demand for the large biological datasets its platforms generate to be used for "training AI models of biology" and also referenced a partnership with Lunit to leverage AI for oncology biomarker discovery.

Competitive Dynamics and Conviction Shifts

The competitive landscape remains intense, with companies focused on building durable moats through technology, scale, and integrated service offerings. MDT was a clear winner on this front, reporting a nine-point U.S. market share gain in the critical Pulsed Field Ablation (PFA) space. TMDX stressed that its vertically integrated platform—spanning technology, logistics, and digital connectivity—creates a "durable moat" that is difficult for competitors to replicate. TXG also strengthened its competitive position via a favorable patent-infringement verdict against Parse Biosciences, as mentioned on its Q2 call. BSX, however, was on the receiving end of competitive headwinds, explicitly calling out "competitive pressure in Electrophysiology" as a key factor in its guidance reduction.

These dynamics drove notable shifts in analyst conviction. Conviction rose most significantly for A (+0.10) and TXG (+0.10), whose strong execution, guidance raises, and promising new product cycles underscored their positive theses. Conviction also increased for MDT (+0.05) and, surprisingly, BSX (+0.05), suggesting that despite the guidance cut, the market may have appreciated the earnings beat and the clear articulation of its challenges. The only negative shift was for TMDX (-0.05); while its top-line growth and long-term strategy remain compelling, the magnitude of its near-term margin reset for strategic investment weighed on sentiment. Conviction remained neutral for ABT, LTRN, ALNY, and NVS, reflecting either steady-state execution or a lack of new catalysts during the period.

Guidance direction

Surprise

Thesis impact

Companies

Sources

The weekly brief

Get a weekly digest of what’s changing.

Research updates, thesis changes and company developments. One email a week.